Synthetic Biologics: Annual ROTH Conference (Synthetic Biologics Press Release) - Mar 14, 2015 - “Phase 2 relapsing-remitting MS clinical data”; “Data supports potential treatment for cognitive dysfunction: Patients in the Trimesta arm with Paced Auditory Serial Addition Test (PASAT) scores lower than 55 before treatment experienced an 12%, or 6% point, improvement in cognitive scores within 12 months (p<0.05)”; “Improvement from baseline was sustained throughout 24 month study”; “Evidence of improvement of physical disabilities: Expanded Disability Status Scale (EDSS) scores in Trimesta arm significantly improved during 24 month follow-up by at least 0.5 point (p=0.03) compared to the active control arm which experienced no change in EDSS scores: The difference between the two groups showed a positive trend (p=0.25); “The 25 foot walk test showed a significant difference, while the patients in the Trimesta arm were stable during the study, those in active control arm did worse: The difference between the two groups (p=0.02)"
P2 data • Multiple Sclerosis
|